First National Bank of Omaha Purchases Shares of 35,814 Icon Plc $ICLR

First National Bank of Omaha acquired a new stake in Icon Plc (NASDAQ:ICLR) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 35,814 shares of the medical research company’s stock, valued at approximately $6,267,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Artisan Partners Limited Partnership grew its holdings in Icon by 67.4% during the second quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after purchasing an additional 2,893,946 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Icon by 21.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock valued at $545,730,000 after buying an additional 650,379 shares during the period. Principal Financial Group Inc. lifted its position in shares of Icon by 739.2% in the third quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock valued at $573,526,000 after buying an additional 2,886,755 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Icon by 3.3% during the 2nd quarter. Invesco Ltd. now owns 3,085,993 shares of the medical research company’s stock worth $448,858,000 after acquiring an additional 98,032 shares during the period. Finally, Ninety One UK Ltd increased its holdings in shares of Icon by 0.4% during the 3rd quarter. Ninety One UK Ltd now owns 3,006,141 shares of the medical research company’s stock worth $526,075,000 after acquiring an additional 12,489 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ICLR shares. Robert W. Baird set a $119.00 price target on Icon in a report on Friday. Leerink Partners restated a “market perform” rating and set a $105.00 target price on shares of Icon in a research note on Thursday, February 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research note on Monday, December 29th. Barclays increased their price target on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Bank of America reaffirmed an “underperform” rating and issued a $75.00 target price on shares of Icon in a research report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $164.33.

Icon Stock Performance

NASDAQ ICLR opened at $88.62 on Wednesday. The firm has a 50-day moving average price of $172.29 and a two-hundred day moving average price of $173.74. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The company has a market capitalization of $7.16 billion, a P/E ratio of 11.99, a P/E/G ratio of 1.96 and a beta of 1.27. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.